< Back to previous page


Dendritic cell immunotherapy in serous ovarian cancer.

Ovarian cancer is the second most important pelvic tumor with limited treatment options in case of relapsing tumors, leading to a poor prognosis. New therapies are needed. Earlier, we developed dendritic cell (DC) immunotherapy for uterine cancers, based on the tumorassociated antigen (TAA) Wilms’ tumor gene 1 (WT1). DCs were produced in the laboratory starting from regular white blood cells from a patient. These DCs were loaded with WT1 in its genetic form (RNA) and then re-injected into the patient, activating defender cells (T cells), which destroy WT1 positive tumor cells. Our first phase I/II trial was completed in 2012 and showed clinical response in 50% of patients. In the current research project, we will design a similar therapy for ovarian cancer with this difference that we will not use one TAA but a combination of tumor lysate together with 3 defined TAAs, mainly to avoid tumor escape. In vitro stimulation experiments to explore this strategy are aimed to support a first clinical trial. The combination of tumor lysate-loaded DCs and DCs loaded with specific TAAs is innovative in the field of immunotherapy. The latter DCs will allow TAA-specific immunomonitoring approaches. For the immunomonitoring of lysate-loaded DCs, we will develop a whole blood culture methodology which will allow us to analyze tumor antigenresponding cells and a mixture of cytokines. With this project, we hope to create a new therapeutic option for relapsing ovarian cancer patients.

Date:1 Oct 2013 →  30 Sep 2016
Keywords:Ovarian cancer
Disciplines:Morphological sciences, Oncology